ANAB: Court Victory Dismisses Tesaro’s Breach Claim!

Overview – Company & Legal Victory

AnaptysBio (NASDAQ: ANAB) is a biotechnology firm that recently transformed into a royalty-focused company. Its fortunes are closely tied to Jemperli (dostarlimab), a cancer immunotherapy originally licensed to Tesaro (now a GSK subsidiary). In April 2026, ANAB scored a significant legal win: the Delaware Chancery Court dismissed Tesaro’s anticipatory breach of contract claim (uk.investing.com). The court found that AnaptysBio had not repudiated the 2014 collaboration agreement governing Jemperli, thereby preserving ANAB’s contractual royalty rates and rejecting Tesaro’s bid to cut those payments (uk.investing.com). This victory removes an immediate threat that could have slashed AnaptysBio’s Jemperli royalties by 50%, a relief that investors cheered. ANAB shares have surged over the past year – up ~274%, recently trading in the mid-$50s per share (≈$1.5 B market cap) (uk.investing.com) – reflecting optimism around its royalty stream and strategic pivots.

The Tesaro/GSK dispute isn’t over yet. While Tesaro’s counterclaim was thrown out, AnaptysBio’s own lawsuit against Tesaro continues (uk.investing.com). ANAB alleges Tesaro breached exclusivity and diligence obligations – for example, by working on competing PD-1 drugs and failing to maximize Jemperli’s commercial potential (uk.investing.com). AnaptysBio is even seeking a reversion of Jemperli rights if Tesaro is found in material breach (uk.investing.com). A trial to adjudicate these claims (and determine if ANAB can reclaim Jemperli) is scheduled for mid-July 2026 (uk.investing.com). In other words, the upside could be huge – regaining full control of an FDA-approved immunotherapy – but the outcome is uncertain. For now, the recent court ruling de-risks the status quo: AnaptysBio retains its valuable royalty stream under the original terms (uk.investing.com) (uk.investing.com). Under that agreement, ANAB earns tiered royalties from 8% on Jemperli sales < $1B up to 25% on sales above $2.5B, through at least 2035 in major markets (uk.investing.com). This tiered structure means if Jemperli’s sales accelerate (as GSK hopes), AnaptysBio’s payout could be substantial – a key long-term value driver. The legal victory ensures ANAB keeps that economic upside intact for now.

Dividend Policy & Shareholder Returns

AnaptysBio has never paid a dividend, and it does not currently plan to start one (www.sec.gov). Like most development-stage biotechs, the company historically reinvested or needed cash for R&D rather than paying shareholders. In fact, management explicitly notes that any stockholder returns have come via stock price appreciation rather than cash dividends (www.sec.gov). This remains true after AnaptysBio’s recent strategic shift – no regular dividend has been initiated, so the dividend yield is 0%.

Don't wait — first dividend checks could arrive any day.

Get the concise guide to start collecting royalty checks now.

Get Instant Access
✕

Instead of dividends, ANAB has favored share repurchases to return capital. The board authorized a $75 M buyback in 2022-2023 (of which $65.2 M was utilized by Q3’25) and, more recently, approved a new $100 M repurchase plan ahead of the spin-off of its R&D assets (www.stocktitan.net) (www.stocktitan.net). This sizable buyback (nearly 7% of the current market cap) underscores confidence in the company’s future cash flows and is intended to reward shareholders. With the business pivoting to a lean, royalty-collection model (discussed below), management appears committed to “returning value” via buybacks (www.stocktitan.net). It’s worth noting that as a cash-rich, asset-light entity post-restructuring, AnaptysBio could consider dividends down the road – the board even acknowledged that possibility once the company separated its pipeline (www.sec.gov). For now, however, no dividend is paid, and share repurchases are the primary form of shareholder yield.

Leverage, Monetization Deals & Debt Maturities

AnaptysBio carries no traditional debt on its balance sheet – no bank loans or bond obligations. The company’s leverage comes mainly from royalty monetization agreements that function like non-recourse debt. In 2022, AnaptysBio sold a portion of its future Jemperli royalties to Sagard Healthcare for an upfront $250 M (later amended with an additional $50 M) (www.sec.gov) (www.sec.gov). Under this deal, Sagard is entitled to Jemperli royalty and milestone payments until it recoups a certain amount (capped at $600 M by 2031, or $675 M if reached later) (www.sec.gov). Once that threshold is met, the Jemperli royalties will revert 100% back to AnaptysBio (www.sec.gov). Importantly, this financing is non-recourse – if Jemperli sales disappoint, AnaptysBio isn’t required to pay Sagard out of other assets (www.stocktitan.net). In accounting terms, the company records a “liability for sale of future royalties” treated as debt, and it amortizes this as royalties are paid to Sagard (www.sec.gov). As of year-end 2025, Sagard had accrued about $250 M in royalties/milestones from Jemperli – roughly 40% of the max payout (www.sec.gov).

Aside from this royalty liability, AnaptysBio’s balance sheet is debt-free. The company had $311.6 M in cash and investments at Dec 2025 (www.sec.gov), bolstered by the monetization proceeds and collaboration payments. After a major corporate reorganization in early 2026 (discussed later), ANAB’s pro forma cash is about $140–145 M (www.stocktitan.net) (www.stocktitan.net). There are no significant loan maturities or interest-bearing debt overhang. The Sagard obligation is the main long-term liability, and notably it is planned to be fully repaid by around Q2 2027 (www.stocktitan.net) (www.stocktitan.net). Management has indicated that accelerating the payoff of this “remaining non-recourse debt to Sagard” is a priority to simplify the capital structure (www.stocktitan.net). This could occur as Jemperli sales and milestones ramp (hitting the payout cap sooner) or potentially via a negotiated pre-payment using cash on hand. In any case, AnaptysBio’s leverage is very low, and it faces no near-term refinancing or maturity risks. The royalty monetization effectively allowed ANAB to fund operations without dilutive equity or conventional debt – at the cost of forgoing some near-term Jemperli cash flows. Now, with a lean cost base, the company can comfortably carry this obligation until it’s done.

Coverage and Cash Flow Sufficiency

Given the lack of traditional debt, interest coverage is a non-issue for AnaptysBio. There are no interest payments to cover (aside from non-cash imputed interest on the royalty liability). More relevant is cash flow coverage of operating needs, and here ANAB appears strong post-restructuring. After spinning off its pipeline, AnaptysBio now operates with an extremely lean model – roughly 10 full-time employees and <$10 M in annualized operating expenses (www.stocktitan.net) (www.stocktitan.net). Essentially all R&D spend has been removed. The company projects a >95% EBIT margin going forward (www.stocktitan.net), since its revenue will come from high-margin royalty/license streams while overhead is minimal. This means that if meaningful royalty income comes in, almost all of it will fall to the bottom line. Even in a downside scenario with modest or delayed royalties, AnaptysBio’s cash reserves (~$140M) are ample to cover many years of its slim operating budget. For perspective, <$10 M annual opex implies well over 10–14 years of runway just from existing cash, even with zero new revenue. In practice, the company is not idle: it already earns some collaboration revenue (e.g. from milestone payments and the Vanda partnership on imsidolimab).

Notably, Vanda Pharmaceuticals filed a BLA for imsidolimab (an ANAB-developed antibody) in generalized pustular psoriasis, which the FDA accepted in Feb 2026 (www.stocktitan.net). If approved, AnaptysBio would receive milestone payments and a royalty on sales of that drug, adding another income source. In 2025, ANAB recognized ~$9.7 M from the Vanda deal for license fees and transition services (www.sec.gov) (www.sec.gov). Moreover, AnaptysBio still books non-cash revenue from Jemperli and Zejula royalties that are being used to service the Sagard and DRI monetization agreements (www.sec.gov). In 2025, for example, it recorded $95.9 M of Jemperli royalty revenue (accounted as paying down the Sagard liability) (www.sec.gov). While these non-cash proceeds don’t immediately boost liquidity, they indicate the growing economic value accruing to ANAB. Actual cash inflows in 2025 included a $75 M milestone payment from GSK for Jemperli’s sales progress (www.sec.gov), which helped AnaptysBio nearly break even (net loss was just $13.2 M) (www.sec.gov).

All told, AnaptysBio’s coverage of obligations is very comfortable now. With virtually no interest or debt service burdens and a very low cash burn rate, the company can sustain itself until larger royalty streams hopefully arrive. Even the planned $100 M stock buyback can be funded without straining resources, given the cash on hand (www.stocktitan.net). In short, operational liquidity is strong, and management has aligned costs to be easily covered by existing capital plus expected partner payments. Investors should monitor the timing of milestone/royalty receipts (e.g. a potential imsidolimab approval milestone or further Jemperli sales milestones), but AnaptysBio has little risk of a cash crunch under current conditions.

Valuation Considerations

Valuing AnaptysBio is a unique exercise now that the company is essentially a royalty holding vehicle. Traditional metrics like P/E or P/FFO are not meaningful at present – AnaptysBio only recently approached breakeven and has fluctuating earnings due to one-time milestones. Funds-from-operations (FFO/AFFO) metrics, typically used for REITs, don’t apply directly here. Instead, investors focus on AnaptysBio’s asset base and future cash flow potential: net cash on hand, plus the present value of expected royalty streams (adjusted for the Sagard deal and litigation outcomes).

At ~$55 per share (post-spin-off), ANAB’s market capitalization is about $1.5 B (uk.investing.com). Subtracting ~$140 M net cash, the enterprise value (EV) is roughly $1.36 B – which can be viewed as the market’s valuation of the royalty rights (Jemperli + imsidolimab + other minor assets). By comparison, in 2025 AnaptysBio’s total collaboration revenue was $234.6 M (www.sec.gov) (www.sec.gov), but the quality of that revenue matters: only ~$84.7 M was actual cash (from milestones and Vanda fees) while the rest was non-cash accounting for royalties used to repay financiers (www.sec.gov). Looking ahead, recurring annual cash revenues might be modest until the Sagard obligation is satisfied (expected by 2027). Investors are thus valuing future cash flows – essentially betting on Jemperli’s commercial success (post-2027) and/or a favorable legal outcome that could accelerate value realization.

One way to gauge valuation is to consider the potential royalty stream value. If Jemperli eventually achieves blockbuster status (multi-billion dollar sales), ANAB’s tiered royalty could be very lucrative. For example, at $2 B in annual sales, AnaptysBio would get roughly ~$300 M/yr (blended ~15% royalty); at $3 B+, the royalty would approach ~$600–750 M/yr (hitting that top 25% tier) (www.sec.gov). Of course, those are optimistic scenarios. Today, Jemperli’s sales are ramping but far below Keytruda or Opdivo levels. Analysts likely model more conservative trajectories. Still, even a few hundred million per year by the 2030s would justify a sizable valuation for ANAB when discounted back, especially given minimal expenses. The market’s $1.5 B valuation implies high expectations: it suggests that investors assign significant probability to either Jemperli royalty cash flows coming through robustly (after 2027) or an outright reversion/settlement outcome that could unlock value sooner (for instance, GSK potentially paying to buy out AnaptysBio’s royalty). Indeed, after the legal win, InvestingPro analysts noted ANAB was trading near their calculated fair value (uk.investing.com), indicating the stock may already price in much of the known upside.

Compared to peers, AnaptysBio’s profile is somewhat novel. It can be likened to a biopharma royalty company. Pure-play royalty firms (e.g. Royalty Pharma or XOMA Corp) often trade on the yield and growth of their royalty portfolios. ANAB’s current EV/cash flow multiple appears high because near-term cash flows are low, but that multiple would compress if/when substantial Jemperli royalties start flowing directly to ANAB in a few years. Price-to-book is also elevated – roughly 4–5x book value – since book value reflects mainly cash (and the royalty receivable net of liability) whereas the market is pricing in intangible future economics. Until clarity on the July trial and Jemperli’s trajectory emerges, valuation will hinge on scenario analysis. Bulls argue the stock is underpinned by eventual large royalties (or a potential takeover by GSK or another party to secure those rights), while bears might counter that the market has run up too fast (note the stock’s 275% gain in one year (www.stocktitan.net)) and that outcomes like reversion are not guaranteed.

In summary, AnaptysBio’s valuation is high relative to current fundamentals, but it reflects the option value in its situation. With a strong cash cushion and minimal burn, downside risk is mitigated; but to justify $1.5–2B market cap, significant royalty streams or a major legal win must materialize. Investors should therefore treat ANAB as a long-dated royalty/legal play. Traditional ratios won’t fully capture that – instead, watch milestones like Jemperli’s sales ramp (which shortens Sagard’s timeline) and the trial outcome, as these will recalibrate what fair value should be.

Key Risks and Red Flags

While AnaptysBio’s prospects are intriguing, there are several risks and red flags to note:

- Litigation Outcome Uncertainty: The ongoing legal battle with Tesaro/GSK is the biggest wildcard. AnaptysBio’s ability to reclaim Jemperli or secure damages is not assured – the July 2026 trial could end with no finding of breach by Tesaro. If ANAB fails to prove Tesaro’s violations, it would lose the chance to revert Jemperli and may have to continue relying solely on royalties (with GSK as steward of the product). Conversely, even if ANAB wins on some claims, the court’s remedy is uncertain. The company itself acknowledges it’s unable to predict “the nature of the remedies either party may obtain… and the timing or amount of royalties from the sales of Jemperli” given the ongoing proceedings (www.stocktitan.net). In short, legal risk is high – outcomes range from transformational (full drug rights returning) to status quo or even delay/appeals. This binary risk will loom until the trial (or a settlement) resolves matters.

- Counterparty Risk – Reliance on Partners: AnaptysBio is now totally dependent on its partners for success. GSK/Tesaro controls Jemperli’s development and commercialization, and ANAB has no say beyond the contract. If GSK under-prioritizes Jemperli or makes strategic missteps, ANAB’s royalty stream could underperform – indeed, that is the crux of ANAB’s complaint (that Tesaro/GSK failed to use diligent efforts for optimum Jemperli returns) (uk.investing.com). On the flip side, if relations remain strained, GSK might be disincentivized to maximize Jemperli (though the lawsuit pressure and GSK’s own investment suggest they won’t abandon it). Similarly, Vanda holds the fate of imsidolimab; any setbacks in Vanda’s trials, regulatory process, or commercial execution will directly hurt ANAB’s potential milestone/royalty receipts. In essence, AnaptysBio has concentration risk – its cash flows hinge on a couple of products run by external companies. Investors must monitor GSK’s oncology strategy (e.g. competing PD-1 combos) and Vanda’s progress closely. If either partner decides to deprioritize or if disputes arise, ANAB has limited recourse (apart from litigation in the Jemperli case, which it pursued).

- Royalty Monetization Drawbacks: The Sagard monetization provided cash upfront but at the cost of forgoing near-term Jemperli income. Through at least 2026, essentially all Jemperli royalties (and some milestones) will go to pay down the $600–675 M owed to Sagard (www.sec.gov). This means ANAB’s own cash inflows from Jemperli will be minimal until that obligation is satisfied (expected by 2027). If Jemperli sales grow slower than expected, Sagard’s cut could extend longer (or forever cap ANAB’s take if sales never reach the threshold). The red flag here is that ANAB’s reported “revenue” can be misleadingly high due to non-cash accounting – e.g. in 2025 it booked $95.9 M in Jemperli royalty revenue (www.sec.gov), but none of that was money ANAB got to use (it went to Sagard). Investors need to recognize this dynamic. The monetization also introduces some interest rate risk (imputed interest expense on the liability) and potentially a cash sacrifice if AnaptysBio chooses to pre-pay it. Any plan to clear Sagard’s debt early (as management is exploring (www.stocktitan.net)) might involve a significant cash outlay or negotiation. While non-recourse, the Sagard deal complicates the financial picture and may dampen distributable cash in the next couple of years.

- Execution and Resource Limits: After the spin-off of its R&D arm (First Tracks Bio), AnaptysBio is operating with a skeletal team (~10 employees) and outsourced functions (www.stocktitan.net). This lean setup keeps costs low, but it also limits ANAB’s capacity to execute on any new initiatives (www.stocktitan.net). If AnaptysBio were to regain rights to Jemperli (a global oncology product), it would suddenly need to scale up or, more likely, find a commercial partner/buyer quickly – a complex task for a tiny organization. Even managing the legal proceedings, business development, and compliance falls on a very small management group. This raises governance and operational risks: key-person risk (a few executives are critical), potential lack of bandwidth for oversight, and reliance on external advisors (the company hired Piper Sandler to advise on strategy (www.stocktitan.net), indicating it may seek outside expertise for major decisions). Any missteps or delays due to limited internal resources could impact shareholder value. Essentially, AnaptysBio is not a “going concern” operating company in the usual sense – it’s more of a royalty trust with a legal battle attached. Investors should be comfortable with that and the unusual management structure (notably, AnaptysBio’s CEO, Daniel Faga, also serves as CEO of the spun-off First Tracks Bio during the transition (ir.anaptysbio.com), which could present conflicts or distraction until the roles fully separate).

- Pipeline and Growth Absence: Post-spin, AnaptysBio has no internal drug pipeline or research engine. This means no obvious growth drivers beyond the existing royalty assets. If Jemperli and imsidolimab perform as hoped, great – but if not, ANAB has little else to fall back on. It’s not investing in new products (aside from perhaps using cash to acquire additional royalty streams, though no such plan is announced). While this focus brings financial discipline, it also makes ANAB’s long-term story finite: royalties run until patents expire (2035–2037 for Jemperli (uk.investing.com), and imsidolimab likely similar if approved). Without reinvestment, the company could effectively wind down after those streams end. The planned spin-off was meant to “unlock the value” of the pipeline in a separate entity (ir.anaptysbio.com), which it did – but that leaves ANAB itself as a shrinking asset unless new deals are made. This could be a risk if management doesn’t find ways to extend or grow the royalty portfolio. It also means ANAB’s valuation is highly sensitive to Jemperli’s competitive environment – e.g. if new cancer therapies diminish the role of PD-1 inhibitors or if pricing pressures hit, royalty projections could be cut with no offsetting business for ANAB.

- Regulatory and Commercial Risk for Royalties: Even for the partnered assets, there are typical pharma risks. Jemperli faces competition from entrenched players (Merck’s Keytruda, BMS’s Opdivo) and is entering crowded indications, which could limit its sales potential. Safety issues or trial failures in expanding Jemperli’s label could also cap growth. For imsidolimab, regulatory approval is not guaranteed – the FDA will scrutinize its risk/benefit in a rare disease. Commercially, Vanda’s ability to market a dermatology orphan drug is unproven. Any such setbacks would directly reduce or delay ANAB’s royalty income. Additionally, royalty streams carry royalty-specific risks like patent validity challenges or royalty disputes (for example, ANAB already had a small legacy royalty on GSK’s Zejula which it monetized and is out of the picture (www.sec.gov), but it shows that patents/IP around a product can affect royalty flow). Investors shoulder these underlying product risks indirectly through ANAB.

- Market Liquidity and Volatility: A practical consideration – after the spin-off, some biotech-focused investors may have sold ANAB to rotate into the pipeline (TRAX) or other growthier names, while income-oriented or event-driven investors came in. This transition can cause volatility. The stock jumped on news of the court win (+13% intraday) (www.stocktitan.net), but it also fell ~12% on the spin-off and buyback announcement day (www.stocktitan.net), showing how sensitive it is to news and expectations. With a ~$1–2B market cap and ~29M shares out, ANAB isn't extremely liquid, and its story is niche – this can mean sharp moves on relatively low volume or sentiment shifts. Investors should be prepared for volatility around news (trial updates, GSK headlines, FDA decisions) and recognize that the stock might not trade on fundamentals in the short-term, but rather on merger/speculation or legal betting.

In sum, AnaptysBio comes with significant risks – legal, operational, and strategic. The company’s narrowed focus and strong cash position mitigate some typical biotech risks (like financing risk), but new ones have emerged (legal/regulatory outcomes, dependence on others). Caution is warranted, and thorough due diligence on the legal case and Jemperli’s market outlook is essential for any investor considering ANAB at these levels.

Open Questions & Wildcards

Finally, here are several open questions that remain for AnaptysBio – factors that could materially influence its future but are not yet resolved:

- Will the July 2026 trial deliver a game-changing outcome? The biggest unknown: can AnaptysBio prove Tesaro/GSK breached the collaboration to the extent that Jemperli rights revert? A court ruling in ANAB’s favor (or a favorable settlement beforehand) could turn the company from a royalty collector into an owner of a high-profile drug. Conversely, if the court rules Tesaro did not breach or grants only minor remedies, ANAB’s upside would be limited to the existing royalty agreement. This binary event will significantly impact the intrinsic value of the stock. Until then, the question of reversion rights hangs in the balance (uk.investing.com) (uk.investing.com).

- Could AnaptysBio and GSK settle their dispute out of court? Litigation is costly and unpredictable. There is speculation that GSK might seek a settlement – for example, buying out AnaptysBio’s royalty interest in Jemperli for a lump sum – especially now that ANAB has the upper hand on the repudiation claim. AnaptysBio engaging an exclusive financial advisor (Piper Sandler) (www.stocktitan.net) hints that it may be exploring strategic options. A settlement could involve GSK paying a hefty amount to eliminate the royalty or litigation risk, which, if attractive enough, ANAB might accept. Alternatively, GSK could wait to see the trial outcome. The question is whether either side blinks before the courtroom showdown. Any sign of settlement talks (or a surprise deal announcement) would be a major catalyst.

- What happens if AnaptysBio regains Jemperli? This is a “good problem” to have, but it raises questions. As noted, ANAB as it stands is not equipped to market a global oncology drug. So if the court grants reversion, how will AnaptysBio monetize or develop Jemperli? Will it immediately auction those rights to big pharma (likely for a multi-billion dollar sum)? Could it consider re-uniting with its spin-off (First Tracks Bio) or another entity to build a commercial capability? Also, how would the Sagard royalty monetization be handled in that scenario – presumably, ANAB would still owe Sagard from Jemperli’s future sales, which any buyer would need to assume or factor into a deal. This could get complex. In essence, a victory could lead to M&A or partnership negotiations for ANAB. Investors would then need to assess what price Jemperli might fetch on the open market. This open question makes ANAB somewhat of a binary play on that legal outcome.

- When and how will the Sagard royalty buyout conclude? Management expects the Sagard liability to be gone by mid-2027 (www.stocktitan.net). The question is: will it reach the threshold naturally through Jemperli sales/milestones, or will ANAB actively pay it down early? If Jemperli’s uptake accelerates (especially with new indications in endometrial, etc.), the $600 M cumulative mark could indeed be hit by 2027, ending the agreement. If not, ANAB might consider using a chunk of its cash (or a new financing) to retire the obligation sooner and capture 100% of royalties thereafter. Any decision on this front – say ANAB announcing it will use $X of its cash to buy down the Sagard agreement – could affect valuations (possibly viewed positively, as it would hasten free cash flow, but it also spends cash). For now, they’ve signaled the intent but not the method (www.stocktitan.net). It’s an open item to watch in coming quarters.

- How successful will Jemperli actually be commercially? Beyond the legal mechanics, the fundamental question is how big Jemperli can grow in the competitive immuno-oncology market. Will it achieve multiple blockbuster indications (challenging Keytruda in some areas, or carving out niches)? GSK is studying Jemperli in combination with other agents, and it recently showed positive data in endometrial cancer. But IO is a crowded field. Sales ramp will determine the long-term royalty stream for ANAB. If Jemperli plateaus at, say, $500 M annual sales, ANAB’s royalties (8–12% tier) would be modest; if it grows to $2–3 B+, ANAB’s 15–25% cut is enormous. Thus far, investors seem optimistic – but it’s an open question whether Jemperli will fulfill that promise. Key milestones to watch: upcoming trial readouts, new approvals (e.g. first-line combos), and GSK’s commitment (they’ve said Jemperli is a growth driver, but also have other pipeline priorities). The magnitude of Jemperli’s success (or lack thereof) will directly answer what ANAB’s cash flows in the 2030s look like.

- Will AnaptysBio initiate a dividend or other capital return as royalties materialize? With the lean cost structure and minimal need for re-investment, AnaptysBio could eventually become a high-yielding entity – essentially passing through royalty income to shareholders (similar to a Royalty Trust model). The board has so far chosen buybacks, but as steady royalty cash comes in (post-2027), a regular dividend might be considered (www.sec.gov). They explicitly noted that after the separation, they may declare dividends depending on financial conditions (www.sec.gov). For income-focused investors, this is an interesting possibility. It remains open when (or if) ANAB might start paying out cash. A related question: will ANAB continue aggressive share buybacks? The current $100 M program is significant. If the stock price remains below management’s view of intrinsic value, they could extend repurchases, effectively shrinking the float and boosting future per-share royalty leverage. How they balance buybacks vs. potential dividends in coming years will be something to monitor, especially once the Sagard overhang is removed and cash begins to accumulate.

- What is the fate of First Tracks Biotherapeutics (spin-off) and does it circle back in any way? AnaptysBio successfully spun off its early-stage pipeline into First Tracks Bio (NASDAQ: TRAX) in April 2026, with First Tracks launching independently with $180 M cash (ir.anaptysbio.com) (ir.anaptysbio.com). Existing ANAB shareholders received one TRAX share per ANAB share (ir.anaptysbio.com). While TRAX’s performance is now separate, an open question is whether any strategic relationship remains. Daniel Faga is CEO of both entities (at least initially) (ir.anaptysbio.com), and some board members overlap, so there is shared DNA. As ANAB focuses on royalties, TRAX is advancing three immunology drug candidates (ANB033, rosnilimab, ANB101) (ir.anaptysbio.com). There’s a scenario in the long run where if, say, TRAX develops a successful drug, ANAB could have interest in getting a royalty or if TRAX struggles, perhaps assets could come back – but these are speculative. Essentially, AnaptysBio is now a separate firm, but investors in ANAB are likely also holders of TRAX stock after the distribution. The question for them is how to value the combined outcome. While beyond ANAB’s direct scope, the spin-off’s success could indirectly benefit ANAB holders who kept their TRAX shares. Conversely, if one wanted pure-play ANAB royalty exposure, they might have sold TRAX. This dynamic is an “open question” in the sense of where shareholders see total value (ANAB + TRAX) going and whether the spin-off unlocked value as intended.

- Will AnaptysBio remain independent for the long haul? Now that AnaptysBio’s business essentially consists of managing royalty streams and legal claims, one wonders if it becomes a takeover target. For instance, Royalty Pharma or other investment firms might find ANAB’s future Jemperli royalties attractive and consider acquiring the company (especially after the litigation is resolved). Alternatively, GSK itself – if it cannot void the royalty contract via court – might choose to buy AnaptysBio outright to eliminate paying royalties through 2035 (this would be analogous to a mining company buying out a royalty interest). With a ~$1.5–2B market cap, ANAB is bite-sized for a pharma or a large fund. The presence of a poison pill or anti-takeover provisions is not known, but management’s hiring of advisors suggests they are open to evaluating all paths. It’s an open question whether ANAB will simply operate as a high-dividend royalty collector for decades or if at some point, a larger player will consolidate it for its cash flows. Any indications of strategic interest (or insider moves in that direction) would be a notable wild card for investors.

In conclusion, AnaptysBio’s story in 2026 is far from over. The company has stabilized its finances and won an important court battle (uk.investing.com), but the real endgame will play out in the coming quarters and years. How the legal drama resolves, how well Jemperli performs, and what management does with its capital will determine whether ANAB delivers outsized rewards or settles into a modest royalty stream. Investors should keep these open questions in mind – the range of outcomes is wide, and due to AnaptysBio’s unusual profile, surprises can significantly change its value. As always, ongoing due diligence (following court filings, GSK’s earnings commentary on Jemperli, FDA news on imsidolimab, etc.) is essential when navigating this complex but compelling equity story.

For informational purposes only; not investment advice.